On one hand, the increased expression of GPX7 and LOX was associated with the chemotherapy resistance of cancer cells to Fluphenazine, arsenic trioxide, nellarabine, erlotinib, and lenvatinib (Supplementary Fig. 4A). Here, LOX is linked to cancer.